Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...
GlobalData on MSN3d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mDaiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope.
Daiichi Sankyo Company, Ltd, an innovative global healthcare company, announced that it will pay Glycotope $132.5 million to acquire intellectual property rights of the antitumor-associated mucin-1 ...
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody ...
5h
The U.S. Food and Drug Administration approved AstraZeneca (AZN, AZN.L) and Daiichi Sankyo's (DSKYF.PK) Datroway (datopotamab ...
Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is ...
Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback